Imara
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
309 Beacon St Ste 300 Ofc 341, Brookline...Phone Number
(617) 206-2020Website
www.imaratx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Imara
Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell disease by both reducing red blood cell sickling and adherence of white blood cells to the blood vessel wall. These combined effects may lead to a lower occurrence of blockage of blood vessels that are underlying causes of the pathology of sickle cell disease. IMR-687 successfully completed a Phase 1 study in healthy volunteers and is currently being evaluated in a multi-national Phase 2a study in adult patients with sickle cell disease. Imara expects to broaden its development of IMR-687, with clinical trials of IMR-687 planned in pediatric patients with sickle cell disease as well as in patients with beta thalassemia, which is a group of geneticRead more
Imara Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imara your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Imara
Website visits: Recent activity has been detected on your website
Click to see if Imara had a recent Job posting/layoffs
Earning: See what the market has to say on Imara recently announced quarterly report
Product Launch: Get notified when Imara launches new products
Funding: Get notified immidiatlly once Imara has new funding data
Check out if Imara is spiking on competitors!
Imara, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Imara has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Imara
Find more new buyers
Compare Similar Companies to Imara
Compare insights from companies similar to Imara, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imara is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imara is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imara.
Imara financials insights
Gather financial insights about Imara, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$31M
2019
Series B
$63M
Imara Tech Stack
A closer look at the technologies used by Imara
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Imara News & Media
IMARA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA
NEW ORLEANS, Jan. 11, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Imara Inc. (the "Company") (NasdaqGS: IMRA) with Enliven Therapeutics, Inc. Under the...STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of IMARA Inc. - IMRA
NEW YORK,, Oct. 18, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...Enliven to enter public markets through reverse merger with Imara - BioPharma Dive
With the IPO market still depleted, Enliven, a precision oncology company, has found a different path to the Nasdaq stock exchange.IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (the “Company”) (NasdaqGS: IMRA) with Enliven Therapeutics, Inc. Under the terms of the proposed transaction, shareholders of Imara are expected to own only approximately 16% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Imara
Sign Up For FreeTo access detailed company insights
Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell diseas... Read More
